Kornimate/medical-research-clean huggingface dataset:
mr-guided laser ablation of hepatic tumors

Conditions: Soft Tissue Tumors

Summary: this is a pilot study to investigate the performance of mr-guided laser induced thermal therapy (litt) in the treatment of liver tumors.


Eligibility criteria:
inclusion criteria: * patients with soft tissue tumor metastases to the liver who are referred to interventional radiology for treatment. * surgery is not a viable or desirable alternative therapy at the time of enrollment * radiation therapy has failed or not indicated or can be safely postponed * tumor size ≤ 5 cm at its largest diameter * tumor position is not in the central liver hilum * performance status is ecog 2 or better in adults * patient is able to undergo mri exclusion criteria: * patients with pacemaker or defibrillator * patients with metallic surgical clips close to the site of the intended ablation * pregnant women * patients with hilar liver lesions
immune function and the progression to t1d

Conditions: Type 1 Diabetes

Summary: to elucidate the mechanisms by which type 1 diabetes-associated genes; ifih1, tyk2, ikzf4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in t cells, inflammatory antigen presenting cells, and abnormal immune function in t cells and b cells.

newly proposed studies will identify the inflammatory cues that draw immune cells into islets for disease initiation (project 1); probe the motility of immune cells through inflamed vasculature to the target organ and antigen priming sites within secondary lymphatics (project 2); and characterize the t1d-associated adaptive immune signatures in blood and immune tissues (project 3). the overall hypothesis of the renewed p01 states: 1) the impact of t1d-risk variants will vary by tissue, cell subset, and activation state, and 2) risk variants, cellular stress, and defects in immunologic pathways are key to engender the autoimmune destruction of pancreatic b-cells that results in t1d.

Eligibility criteria:
inclusion criteria: able to have blood drawn - exclusion criteria: none -
intensive rehabilitation of patients with severe traumatic brain injury - development of a didactic model

Conditions: Craniocerebral Trauma

Summary: the aim of the study is to develop a research-based pedagogic model to improve the interaction between the patient's motivation, influence and learning.the hypothesis is: a neuro-rehabilitation effort in patients with severe traumatic brain injury based on a didactic model for improvement of motivation, involvement and re-learning of daily life competences will * improve the patients experience of meaningful learning and influence * provide staff with a tool which contributes to the experience to work in a targeted way concerning motivation, patient influence and re-learning daily life competencies the aim of the study is to develop a research-based didactic model to improve the interaction between the patient's motivation, influence and learning.

annually, about 7500 people get a traumatic brain injury (tbi) in denmark. according to danish and international experiences 250 of these get severe injuries. about 120 younger people often males need highly specialised neuro-rehabilitation at one of the two regional centres in denmark. due to the limited amount of research in this field it cannot be documented but assumed, that the patient's motivation and involvement in planning and implementation of rehabilitation improve subjective and objective outcome. motivation, involvement and learning in patients with severe traumatic brain injury constitute a major challenge. the cases are individual, but often involve disturbances in language and perception, lack of realization, reduced initiative, tiredness and depression. the focus of this project is the intensive physical and psychosocial rehabilitation viewed as a process of relearning targeted daily life competences using the icf levels of function, activity and participation.

Eligibility criteria:
inclusion criteria: 1. severe traumatic brain injury (gcs 3-9) 2. older than 18 years 3. post traumatic amnesiphase (pta) at the end, 4 ranchos los amigos (rlas) score at minimum 4 4. informed consent exclusion criteria: 1. younger than 18 years 2. in pta phase 3. rlas score lower than 4 4. no informed consent

Keywords: severe traumatic brain injury intensive neurorehabilitation "patient participation"[professional-patient relations" re-learning daily life activities rehabilitation
ٍٍsofosbuvir/simeprevir/daclatasvir/ribavirin and hcv genotype 4-infected egyptian experienced participants

Conditions: Chronic Hepatitis C Virus Infection

Summary: experienced participants who had hcv gt4 infection were treated with sofosbuvir/simeprevir/daclatasvir/ribavirin (sof/smv/dcv/rbv)

experienced participants, who had chronic infection with hcv gt4 , and failed prior daa treatments, sof/dcv (71/92) or sof/smv (15/92) or sof/pegylated interferon/rbv (2/92) or sof/rbv (4/92) were enrolled in the current study. in the present study, the regimen used was designed by the combination of triple daas with different mechanisms of action and non-overlapping resistance profiles, sof/smv/dcv, plus rbv.

Eligibility criteria:
inclusion criteria: * experienced egyptian participants with hcv gt4 infection who had failed prior daa treatments \[sof/dcv or sof/smv or sof/pegylated interferon/rbv or sof/rbv\] * fibrosis-4 score in non-cirrhotic participants is \<1.45-3.25: (none or moderate fibrosis) * fibrosis-4 score in cirrhotic participants is \>3.25: (advanced fibrosis or cirrhosis) exclusion criteria: * hcv coinfected with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) * had any liver disease other than chronic hcv gt4 infection. * had a history of liver decompensation * serum a-fetoprotein (afp) \> 100 ng/ml * evidence of hepatocellular carcinoma * major severe illness such as respiratory, renal, heart failure or autoimmune disease * non-compliance with treatment.

Keywords: chronic hcv gt4 sofosbuvir simeprevir daclatasvir ribavirin experienced
shingrix in patients with rheumatic diseases: a double-blind placebo-controlled rct

Conditions: Herpes Zoster

Summary: a double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted dmard therapies

a double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted dmard therapies. duration of study: 60 weeks

Eligibility criteria:
inclusion criteria for patients: 1. patients with a diagnosis of rheumatic or immune-mediated diseases eg. sle, ra, psa, spa, inflammatory myopathies, anca-related and large vessel vasculitides 2. age ≥18 years 3. stable or reducing doses of any the following immunosuppressive regimens within 4 weeks of study entry: 1. prednisolone ≥20mg/kg/day ± mycophenolate mofetil, azathioprine or the calcineurin inhibitors 2. cyclophosphamide (intravenous pulses or daily oral) 3. b-cell depleting biological agents and their biosimilars eg. belimumab, anti-cd20 agents (next scheduled dose should be arranged to at least 12 weeks after study entry for rituximab or obinutuzumab) 4. anti-tnfα biological agents and their biosimilars eg. infliximab, etanercept, adalimumab, golimumab, certolizumab 5. anti-interleukin-6 biological agents eg. tocilizumab, sarilumab 6. other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab 7. the jak inhibitors eg. tofacitinib, baricitinib, upadacitinib 4. female patients with reproductive potential are allowed to participate in this study provided that they are willing to practice contraception for until at least 12 months after vaccination 5. willing to comply with all study procedures exclusion criteria for patients: 1. active infection, including upper respiratory tract infection 2. active hz infection 3. active untreated tuberculosis 4. hiv infection 5. history of hz or varicella vaccination in the past 6. history of allergy to any vaccines 7. patients who are pregnant or plan to become pregnancy within one year of study entry 8. lactating women 9. patients who cannot give a written consent (mentally incapable or illiterate)

Keywords: vaccine rheumatic diseases immunosuppressive immunogenicity biologics targeted dmards
mechanism of effectiveness of neurosurgery treatments for durable pain

Conditions: Oncology Problem

Summary: the participants in the study are patients who undergo surgery to damaged nerve transmission and processing system in the nervous system as part of the routine clinical treatment that will not be affected by the proposed study. patients who are candidates for procedures are referred from all over the country and undergo a multidisciplinary evaluation in the framework of the palliative pain management clinic, which operates exclusively in israel at the sourasky medical center in tel aviv.

the participants in the study are patients who undergo surgery to damaged nerve transmission and processing system in the nervous system as part of the routine clinical treatment that will not be affected by the proposed study. patients who are candidates for procedures are referred from all over the country and undergo a multidisciplinary evaluation in the framework of the palliative pain management clinic, which operates exclusively in israel at the sourasky medical center in tel aviv. during the preoperative evaluation, patients will be given an explanation about the possibility of participating in the study. patients who agree to participate will sign an informed consent form.

Eligibility criteria:
inclusion criteria: * patients undergoing neurosurgical surgery for resistant pain * ability to sign informed consent form for participation in the study * a functional level is sufficient for cooperation and the performance of various tasks before and after surgery, including performing mri's, answering pain questioners, and neuropsychological evaluations. exclusion criteria: * refusal to participate * pregnant women

Keywords: resistant pain
evaluation of exenatide in patients with diabetic neuropathy

Conditions: Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathy

Summary: this study will look at whether or not the medication exenatide improves signs and symptoms of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate diabetic peripheral neuropathy.

this study will look at the effects of the medication exenatide on peripheral neuropathy in people with type 2 diabetes. exenatide (trade name, byetta®) is an injectable medication used by people with type 2 diabetes to control blood sugar. peripheral neuropathy is a complication of diabetes that can cause symptoms such as numbness, tingling or burning sensations in the feet and hands. controlling blood sugars levels in type 2 diabetes is thought to prevent, delay or improve the damage to the nerve fibers that causes peripheral neuropathy. there is also some evidence that exenatide may have additional beneficial effects on the peripheral nerves, beyond the benefits of blood sugar control alone. in this study, about half of the participants will take exenatide by injection twice daily and the other half will take insulin glargine (lantus®) by injection once daily. both groups are expected to have similar improvement in blood sugar control. this study will show whether exenatide has beneficial effects on neuropathy beyond the benefits of better blood sugar control alone.

Eligibility criteria:
inclusion criteria: * type 2 diabetes treated with one or more oral agents * persistent fasting glucose \> 140 mg/dl or hba1c \> 7% * stable and maximally effective doses of one or more oral agents for 3 months * presence of diabetic peripheral neuropathy * age between 18 and 70 years * no risk factors or other causes of neuropathy * willingness and capacity to sign the institutional review board approved consent form and cooperate with the medical procedures for study duration exclusion criteria: * nursing mothers or pregnant women * a history of previous kidney, pancreas or cardiac transplantation * a past history of neuropathy (independent of diabetes) or with a disease known to be associated with neuropathy (e.g., hepatitis c, end stage renal disease, lupus) * amputation of any part of either lower extremity for any reason or traumatic loss of any part of either lower extremity or congenital absence or severe deformity of lower extremity * hba1c \> 10% * participation in an experimental medication trial within 3 months of starting the study. * undergoing therapy for malignant disease other than basal- or squamous cell carcinoma * requiring long-term glucocorticoid therapy * inability or unwillingness to comply with the protocol

Keywords: diabetes neuropathy glucose control peripheral autonomic
4-ever : a trial investigating the safety of 4f endovascular treatment of infra-inguinal arterial stenotic disease

Conditions: Peripheral Vascular Disease; Claudication

Summary: the objective of this clinical investigation is to evaluate puncture site complication rate as well as the short- and long-term (up to 24 months) outcome of treatment by means of astron pulsar / astron pulsar-18 stent implantation in symptomatic (rutherford 2-4) femoro-popliteal arterial stenotic or occlusive lesions, using 4f compatible devices of biotronik and without the use of a closure device. the hypothesis is that the primary patency at 12 months is non-inferior to the primary patency obtained in the durability study (72.2%).


Eligibility criteria:
inclusion criteria: * de novo, restenotic or reoccluded lesion located in the femoropopliteal arteries suitable for endovascular treatment * patient presenting with a score from 2 to 4 according to the rutherford classification * patient is willing to comply with specified follow-up evaluations at the predefined time intervals times * patient is \>18 years old * patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study * prior to enrollment, the target lesion was crossed with standard guidewire manipulation * patient is eligible for treatment with 4f compatible devices angiographic inclusion criteria: * the target lesions are located within the native superficial femoral artery: distal point 3 cm above knee joint and 1 cm below the origin of the profunda femoralis. * the target lesion has angiographic evidence of stenosis or restenosis \> 50% or occlusion * length of the target lesion is =20 cm by visual estimation and can be covered with one stent * target vessel diameter visually estimated is =4 mm and =6.5 mm * there is angiographic evidence of at least one-vessel-runoff to the foot exclusion criteria: * presence of another stent in the target vessel that was placed during a previous procedure * presence of an aortic thrombosis or significant common femoral ipsilateral stenosis * previous bypass surgery in the same limb * patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics * patients who exhibit persistent acute intraluminal thrombus at the target lesion site * perforation at the angioplasty site evidenced by extravasation of contrast medium * patients with known hypersensitivity to nickel-titanium * patients with uncorrected bleeding disorders * female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding * life expectancy of less than 12 months * ipsilateral iliac artery treatment before target lesion treatment with a residual stenosis \> 30% * use of thrombectomy, atherectomy or laser devices during procedure * any planned surgical intervention/procedure 30 days after the study procedure * any patient considered to be hemodynamically unstable at onset of procedure * patient is currently participating in another investigational drug or device study that has not reached the primary endpoint

Keywords: peripheral vascular disease claudication rest pain
an observational study of predictors and outcomes of lung cancer in never-smokers in the uk

Conditions: Lung Cancer

Summary: the goal of this observational study is to improve the early detection of lung cancer in adults who have smoked less than 100 tobacco cigarettes ("never-smokers") in the united kingdom. the main questions it aims to answer are: * to describe characteristics such as demographics, co-morbidities and environmental exposures * to describe participant pathways including presentation mode and symptoms to understand if earlier diagnosis would be possible * to describe participant outcomes such as cancer stage, treatment and mortality * to quantitatively or qualitatively measure modifiable and non-modifiable factors that may be associated with lcins including environmental measures, blood tests and genomic data. participants will currently have no change to their usual care.


Eligibility criteria:
inclusion criteria: * all adult participants from age of 18 who are diagnosed or treated with primary lung cancer through radiology or histology at any participating study site exclusion criteria: * participants who have ever smoked cigarettes or tobacco will be excluded; this is defined as: * more than 100 cigarettes or 75g tobacco in their lifetime * those who have received a prescription for nicotine replacement therapy * for prospective participants, those who cannot consent will be excluded
robotic oct for er anterior eye exams

Conditions: Develop and Test Robotically Assisted Imaging System for the Front of the Eye

Summary: the purpose of this study is to develop and test a robotically assisted imaging system for the front of the eye with a goal of helping eye care through the emergency department.


Eligibility criteria:
inclusion criteria: * adult patients 18 years of age and older * presenting with ocular complaints potentially indicative of an anterior segment pathology (e.g., foreign body sensation, red eye, pain) exclusion criteria: * hemodynamically unstable patients (e.g., undergoing active resuscitation efforts) * patients with potential penetrating trauma to the eye who may need immediate surgical care
effect of polyherbal compound for control of blood sugar in impaired glucose tolerance and diabetes

Conditions: Diabetes Mellitus

Summary: the aim of the study is to control blood sugar with sugar balance capsules which is the leaves of three herbs: ivy ground (coccinia indica)-200mg, bougainvillia (bougainvillea spectabilis)-30mg, madagascar periwinkle (catharanthus rosea)-20mg.


Eligibility criteria:
inclusion criteria: * adult males and non-pregnant females aged ≥30 years having a diagnosis of pre-diabetes (impaired fasting glucose or impaired glucose tolerance) and a diabetes and a meeting one of the following criteria 1. fasting plasma glucose ≥100 mg/dl, fasting is defined as no caloric intake for at least 8 h, or 2. 2-h post load glucose ≥140 mg/dl during an oral glucose tolerance test (ogtt). the test should be performed as described by the world health organisation(who), using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. or 3. glycosylated haemoglobin (a1c) ≥5.7%. the test should be performed in a laboratory using a method that is national accreditation board for testing and calibration laboratories certified and standardized. or 4. in a patient with classic symptoms of hyperglycaemia or hyperglycaemic crisis, a random plasma glucose ≥200 mg/dl in the last 12 months. exclusion criteria: * any one of the following 1. history of diabetes onset \>12 months from date of randomization and/or on any oral hypoglycemic agents (other than metformin) 2. any history suggestive of micro vascular or macro vascular disease 3. women in childbearing age unable to practice any form of contraception 4. impaired renal function; estimated glomerular filtration rate(egfr) \<60mls/min/1.73m2. 5. known history of any chronic illness taking regular pharmacological agents. 6. blood pressure fluctuations exceeding 10 mmhg on 2 subsequent clinic visits or known history of hypotension or bradycardia in last 6 months or taking 2 or more antihypertensive medications regularly in the last 6 weeks 7. current or former employees of organic india 8. participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days. 9. refusing consent or physician uncomfortable with patient compliance to treatments or follow up.
safety and efficacy of miw815 (adu-s100) +/- ipilimumab in patients with advanced/metastatic solid tumors or lymphomas

Conditions: Advanced/Metastatic Solid Tumors or Lymphomas

Summary: the purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of miw815 (adu-s100) administered via intratumoral injection as a single agent and in combination with ipilimumab.


Eligibility criteria:
inclusion criteria: * ecog ≤ 1 * willing to undergo tumor biopsies from injected and distal lesions * must have two biopsy accessible lesions: * \* one lesion must be ≥10 mm and \<100 mm in longest diameter, accessible for repeated intratumoral (it) injection and accessible for baseline and on-treatment biopsies. * a second (distal) lesion must be accessible for baseline and on-treatment biopsy and must be distinct from the injected lesion. * tumors encasing major vascular structures (i.e., carotid artery or tumors close to other vital organs), are not considered appropriate exclusion criteria: * patients who require local palliative measures such as xrt or surgery * symptomatic or untreated leptomeningeal disease. * presence of symptomatic central nervous system (cns) metastases * impaired cardiac function or clinically significant cardiac disease * active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy. * active infection requiring systemic antibiotic therapy. * known history of human immunodeficiency virus (hiv) infection. * active epstein-barr virus (ebv), hepatitis b virus (hbv) or hepatitis c virus (hcv) * malignant disease, other than that being treated in this study.
identification of predictive factors for observance of transcutaneous electrical neurostimulation (tens) in chronic pain

Conditions: Chronic Pain

Summary: this is a retrospective and transverse multicenter study to identify predictive factors for adherence to tens by chronic pain patients followed in structures specialized in chronic pain management (spc). the study contains 2 parts: * a retrospective part of data collection in the patient follow-up file of the spc during the 6 months elapsed after the first rental prescription. * a transversal part, aimed at collecting additional information on the use of tens, satisfaction and quality of life during a telephone interview after 6 months of use.


Eligibility criteria:
inclusion criteria: * aged 18 and over when tens was implemented. * suffering from chronic pain. * follow-up in nurse consultation within a centre specialized in chronic pain management identified and labeled by a local regulatory agency. * benefiting from the implementation of tens for more than 6 months by a nurse from a centre specialized in chronic pain management. * affiliate or beneficiary of a health insurance scheme. * for patients in the study population: having expressed their non-opposition to participate in the study. * patient used to verify the representativeness of the population studied: unable to be contacted by phone and not having expressed their refusal to participate or for which the mail has not returned undelivered non-inclusion criteria * minor. * major incapable to oppose to the use of their data during the study due to medical or legal decision. * having language impairment. * having difficulties understanding the french language. * unable to participate in the phone survey. * not affiliated with health insurance / social security.

Keywords: tens predictive factors compliance chronic pain